Skip to content

An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry

An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02677961
Enrollment
1500
Registered
2016-02-09
Start date
2015-07-01
Completion date
2027-12-31
Last updated
2026-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Neoplasms, Neoplasms, Connective and Soft Tissue

Keywords

sarcoma, registry

Brief summary

Translational studies in cancer research can be impeded by the lack of high-quality clinical data that can be correlated with research questions. This is particularly true in the case of rare diseases, such as bone and soft tissue tumors. It is therefore the purpose of this study to create a prospective EHR-based clinical registry for individuals with bone and soft-tissue tumors.

Detailed description

PRIMARY OBJECTIVES: I. To create a secure EHR-based registry to allow for the prospective collection of clinical and research data in a collection of rare diseases (bone and soft-tissue tumors). II. To facilitate the identification and validation of clinical and molecular features that may be associated with prognosis and/or response to therapy in (subtypes) of bone and soft-tissue tumors. III. To pilot a mechanism that will facilitate future collaboration between institutions for research and analysis of bone and soft-tissue tumors. IV. To standardize biospecimen collection for correlative biomarker analysis for patients undergoing treatment and surveillance for bone and soft tissue tumors at Ohio State University. OUTLINE: This is an observational study. Patients complete quality of life questionnaires and their medical records are reviewed. Patients may also undergo collection of blood samples for up to 2 years, unless otherwise specified in the protocol.

Interventions

OTHERObservation

Sponsors

Ohio State University Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must have a diagnosis or presumed diagnosis of bone or soft tissue tumor as defined by the WHO classification of tumors of soft tissue and bone (4th ed.) * Patient, or his/her designated power of attorney, must be able to understand and approve of the consent to participate.

Exclusion criteria

* Prisoners are excluded from participation in the Registry.

Design outcomes

Primary

MeasureTime frame
Overall Survival5 Years

Countries

United States

Contacts

CONTACTErin Fetzer
erin.fetzer@osumc.edu
CONTACTDavid A Liebner, MD
David.Liebner@osumc.edu(614) 293-2886
PRINCIPAL_INVESTIGATORDavid A Liebner, MD

Ohio State University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 30, 2026